AVI Gets Green Light for Ebola Trial
Luke Timmerman12/24/08
AVI Biopharma, a Portland, OR-based drug developer, said it has “verbal clearance” from the FDA to start clinical trials against the deadly Ebola and Marburg viruses. AVI expects to get a formal written go-ahead from the FDA in early 2009, the company said. Shares of the company (NASDAQ: AVII) shot up 63 percent to 80 cents shortly after the opening bell.
Luke Timmerman is the National Biotech Editor of Xconomy, and the Editor of Xconomy Seattle. E-mail him at ltimmerman@xconomy.com or follow him on Twitter at twitter.com/ldtimmerman.
